Please confirm that your email address is correct, so you can successfully receive this alert.
To the Editor: Recently, omega-3 polyunsaturated fatty acid augmentation of antidepressant medications was demonstrated as providing significant benefit in a 4-week, parallel-group, double-blind study (1) and our 8-week study (unpublished data of K.-P. Su et al.).
Depression during pregnancy affects both the mother and the child. Most drugs pass from mother to baby through the placenta in different degrees. Medicating depressed pregnant patients is a clinical dilemma. Omega-3 polyunsaturated fatty acids, with a possible antidepressant effect (1) and a lack of teratogenicity for the fetus (2), seem to be a favorable treatment alternative. We report here what is to our knowledge the first case of successful treatment with omega-3 polyunsaturated fatty acid monotherapy of a pregnant patient with major depressive disorder.
Ms. A was a 34-year-old married woman who came to our psychiatric service for a recurrent depressive episode at the 24th week of pregnancy. She had had a first major depressive episode 5 years earlier, when she was pregnant with her first baby. Ms. A did not receive any drugs, and the depressive episode remitted 9 months after childbirth. She had another two major depressive episodes between these two pregnancies, and she responded well to paroxetine, 20 mg/day.
When she came to our hospital, Ms. A refused antidepressant agents because of possible teratogenic effects and took only lorazepam, as needed, for insomnia. She did not have any history of substance abuse or any significant medical condition that might account for her depression. The results of laboratory tests (CBC and blood chemistry) were within normal limits.
Ms. A signed our informed consent form and began to take 4 g of ethyl eicosapentaenoic acid (EPA) and 2 g of docosahexanoic acid (DHA) per day, beginning in the 25th week of gestation. She was rated with the 21-item Hamilton Depression Rating Scale at every visit: weeks 0 (before EPA-DHA supplementation), 2, 4, 6, 10, and 18 (6 weeks after delivery).
Ms. A did not have any change in score between weeks 0 (Hamilton depression scale score=28) and 2 (score=29) but showed improvement in depressed mood, anhedonia, feelings of worthlessness, hopelessness, and guilt at week 4 (score=18) and experienced the disappearance of suicidal ideation at week 6 (score=10). After that, only initial insomnia and anxious feelings bothered Ms. A occasionally (week 10: score=6). She received paroxetine, 20 mg/day, after delivery, and her condition has remained stable (week 18: score=7). The baby was delivered and appeared normal in a general physical and neurobehavioral examination at birth.
We have previously reported on a pregnant woman with acute schizophrenia who showed improvement after omega-3 polyunsaturated fatty acid monotherapy (3). We believe that this case is the first report of a pregnant patient with major depressive disorder who was treated with omega-3 polyunsaturated fatty acid monotherapy. Since the patient received regular follow-up for 6 weeks before treatment with omega-3 polyunsaturated fatty acids, it is unlikely that the remarkable improvement was due to the clinical attention of regular visits. Because the patient had a depressive episode during her first pregnancy and after childbirth, we do not think that she had a spontaneous remission from this episode. Her improvement of depression was likely due to omega-3 polyunsaturated fatty acid treatment.
Reduced maternal DHA status after the second trimester (4) is associated with a high demand from the developing fetus for the rapid formation of its brain. Empirical studies of polyunsaturated fatty acids in the tissues (5), data from epidemiologic surveys (6), and results of therapeutic trials of polyunsaturated fatty acids (1) suggest that a deficit in omega-3 polyunsaturated fatty acids might cause major depressive disorder (7, 8). Supplementation with omega-3 polyunsaturated fatty acids is thought to have protective effects for pregnancy outcome in high-risk pregnancy (2). Because of its safety and psychotherapeutic effects, as well as its promotion of health for mothers and their infants, treatment with omega-3 polyunsaturated fatty acids is a promising approach for pregnant patients with major depressive disorder.
Download citation file:
Web of Science® Times Cited: 32